Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption

Wenlin Ren^{1*}, Jun Lan^{2*}, Xiaohui Ju^{1*}, Mingli Gong^{1*}, Quanxin Long³, Zihui Zhu¹, Yanying Yu¹, Jianping Wu⁴, Jin Zhong⁵, Rong Zhang⁶, Shilong Fan², Guocai Zhong^{7, 8}, Ailong Huang³, Xinquan Wang^{2†}, Qiang Ding^{1†}

¹ Center for Infectious Disease Research, School of Medicine, Tsinghua University, Beijing 100084, China

² Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China

³ Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China

⁴ Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

⁵ Unit of Viral Hepatitis, Institut Pasteur of Shanghai, CAS Key Laboratory of Molecular Virology and Immunology, Chinese Academy of Sciences, Shanghai, China,

⁶ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Biosafety Level 3 Laboratory, Fudan University, Shanghai 200032, China

⁷ Shenzhen Bay Laboratory, Shenzhen 518132, China

⁸ School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China

†Corresponding authors: xinquanwang@tsinghua.edu.cn (X.W.); qding@tsinghua.edu.cn (Q.D.);

*These authors contributed equally to this work.

Abstract

COVID-19 patients transmitted SARS-CoV-2 to minks in the Netherlands in April 2020. Subsequently, the mink-associated virus (miSARS-CoV-2) spilled back over into humans. Genetic sequences of the miSARS-CoV-2 identified a new genetic variant known as “Cluster 5” that contained mutations in the spike protein. However, the functional properties of these “Cluster 5” mutations have not been well established. In this study, we found that the Y453F mutation located in the RBD domain of miSARS-CoV-2 is an adaptive mutation that enhances binding to mink ACE2 and other orthologs of *Mustela* species without compromising, and even enhancing, its ability to utilize human ACE2 as a receptor for entry. Structural analysis suggested that despite the similarity in the overall binding mode of SARS-CoV-2 RBD to human and mink ACE2, Y34 of mink ACE2 was better suited to interact with a Phe rather than a Tyr at position 453 of the viral RBD due to less steric clash and tighter hydrophobic-driven interaction. Additionally, the Y453F spike exhibited resistance to convalescent serum, posing a risk for vaccine development. Thus, our study suggests that since the initial transmission from humans, SARS-CoV-2 evolved to adapt to the mink host, leading to widespread circulation among minks while still retaining its ability to efficiently utilize human ACE2 for entry, thus allowing for transmission of the miSARS-CoV-2 back into humans. These findings underscore the importance of active surveillance of SARS-CoV-2 evolution in *Mustela* species and other susceptible hosts in order to prevent future outbreaks.

Key words: COVID-19, SARS-CoV-2, ACE2, mink, animal-to-human transmission, adaptive mutation

Introduction

Coronaviruses are enveloped, positive-stranded RNA viruses that circulate broadly among humans, other mammals, and birds and can cause respiratory, enteric, and hepatic disease¹. In the last two decades, coronaviruses have caused three major outbreaks: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and the recent Coronavirus Disease 2019 (COVID-19)^{2,3}. COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat.

The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein binds its cellular receptor angiotensin-converting enzyme 2 (ACE2), thus mediating viral entry^{4,5}. It has been demonstrated that the interaction of a virus with (a) species-specific receptor(s) is a primary determinant of host tropism and constitutes a major interspecies barrier at the level of viral entry⁶. Our previous study found that numerous mammalian ACE2 orthologs could function as receptors to mediate virus entry *in vitro*⁷, and other studies have demonstrated that rhesus macaques, dogs, cats, cattle, hamsters, ferrets, minks and other animals are susceptible hosts⁸⁻¹³. Together, these findings suggest that SARS-CoV-2 has a broad host range, with many species that could serve as potential reservoirs and thus pose a risk for spillover to humans in the future⁷.

Recently, the first animal-to-human transmission of SARS-CoV-2 was reported^{14,15}. In April 2020, SARS-CoV-2 was transmitted to minks at two farms in the Netherlands by infected employees, and the virus subsequently circulated among the minks^{16,17}. On 5 November 2020, the Danish public health authorities reported 214 cases of humans infected with mink-associated SARS-CoV-2 variants (miSARS-CoV-2) containing a combination of mutations not previously observed¹⁵. Genetic analysis grouped the miSARS-CoV-2 variants into 5 clusters with seven mutations¹⁸. Of note, the “Cluster 5” variant with four amino acid changes in the spike protein was identified in mink and isolated from 12 human cases in North Jutland^{14,18}. The implications of the mutations in this variant are not yet well characterized. Preliminary results suggested that the “Cluster 5” miSARS-CoV-2 strain has moderately decreased sensitivity to neutralizing antibodies^{14,19,20}. Further

investigations are urgently needed to dissect the biological significance of these mutations and to understand the implications of these identified changes for diagnostics, therapeutics and vaccine development.

In this study, we demonstrate that the Y453F mutation in the miSARS-CoV-2 spike is an adaptive mutation that increases interaction with mink ACE2 without compromising utilization of human ACE2. In addition, the miSARS-CoV-2 exhibited partial resistance to neutralization with convalescent serum. Our study not only provides critical insights into viral adaption and evolution but also highlights the importance of surveillance of viral variants in animals to reduce the risk of the emergence of new viral variants and prevent future outbreaks.

RESULTS

Potential impact of the Y453F substitution on the binding of SARS-CoV-2 spike to mink ACE2

Sequence analysis of the miSARS-CoV-2 "Cluster 5" variant isolated from patients identified four mutations in the spike protein: del 69–70 (a deletion of the His69 and Val70), Y453F (located in the RBD), I692V, and M1229I¹⁴ (**Fig. 1A**). Based on the structure of SARS-CoV-2 spike bound to human ACE2^{21–24}, Y453 in the spike protein can form hydrogen bonds with H34 in human ACE2 (**Fig. 1B and C, left panel**); however, mink ACE2 has a Tyr at the 34th position, which is predicted to cause a spatial clash with Y453 (**Fig. 1B and C, right panel**) and impair interaction with mink ACE2. This is supported by the limited binding affinity observed between WT SARS-CoV-2 RBD and mink ACE2 (**Fig. 2A and B**), and the finding that mink ACE2 mediates authentic SARS-CoV-2 entry with 20–30% efficiency of human ACE2⁷. Based on this analysis, we hypothesized that the Y453F substitution evolved in the miSARS-CoV-2 spike RBD as it enhances interaction with mink ACE2, conferring a fitness advantage in the new host and leading to circulation of the adapted virus in the mink population.

The Y453F mutation in miSARS-CoV-2 spike increases interaction with mink ACE2

To test our hypothesis, we first employed a cell-based assay, using flow cytometry to assess the binding of S protein to ACE2 orthologs and variants (**Fig. 2A**). We cloned the cDNA of ACE2 variants, each with a C-terminal FLAG tag, into a bicistronic lentiviral vector that expresses the fluorescent protein zsGreen1 via an IRES element (pLVX-IRES-zsGreen1) and can be used to monitor transduction efficiency. Next, WT or Y453F S1-Fc (a purified fusion protein consisting of the S1 domain of SARS-CoV-2 S protein and an Fc domain of human IgG) was incubated with HeLa cells transduced with the ACE2 variants. Binding of S1-Fc to ACE2 was then quantified by flow cytometry as the percent of ACE2-expressing cells positive for S1-Fc (**Fig. S2 and Fig. 2B**).

As expected, the binding of S1-Fc or S1 (Y453F)-Fc to HeLa cells expressing mouse ACE2 was very low and comparable to that of the empty vector control while S1-Fc efficiently bound to HeLa cells expressing human ACE2, which is consistent with previous reports⁵. S1 (Y453F)-Fc bound human ACE2 more efficiently than WT S1-Fc (99.1% vs 86.5%). Notably, WT S1-Fc bound mink ACE2 with limited efficiency, but in contrast, S1 (Y453F)-Fc bound mink ACE2 with 77% efficiency, demonstrating that the miSARS-CoV-2 mutation enhances binding to mink ACE2. Moreover, after replacing the amino acid residue at position 34 of human ACE2 with its mink counterpart to generate human ACE2 (H34Y), binding to S1-Fc was reduced (86.5% [WT] vs 42.0%) but increased to S1 (Y453F)-Fc (92.25% [WT] vs 98.38%). Performing the converse by substituting the amino acid residue at position 34 of mink ACE2 with its human counterpart to generate mink ACE2 (Y34H) only slightly increased binding to S1-Fc (0.04% vs 0.92%) and decreased binding to S1(Y453F)-Fc (45.05% vs 42.17%) (**Fig. 2B**).

As we used cell-surface staining of ACE2 to sort the cells used for these experiments so that they had comparable ACE2 expression, the limited or undetectable binding of certain ACE2 variants with the S1 variants was not due to low expression of ACE2 or alteration of its cell surface localization (**Fig.S1A**). The expression level of the ACE2 variants was also assessed by immunoblotting using an anti-Flag antibody and cell surface localization by immunofluorescent microscopy (**Fig. 2C and D**). Together, these results showed that all the ACE2 orthologs were expressed and localized at the cell surface at comparable levels, excluding the possibility that the limited binding efficiencies of ACE2 orthologs with S1-Fc variants was attributable to varied cell surface localization.

To further quantify the binding of ACE2 variants with the spike protein variants, we expressed and purified recombinant WT and Y453F SARS-CoV-2 RBD as well as ACE2 variants to assay binding *in vitro* by surface plasmon resonance (SPR) analysis (**Fig. S3A-B and Fig. 2E**). Mink ACE2 bound Y453F SARS-CoV-2 with a K_D of 78.22nM but binding to WT RBD was not detectable. Human ACE2 bound SARS-CoV-2 RBD with a K_D of 6.5nM, and Y453F RBD with a K_D of 0.98nM. These SPR results are thus consistent with the

findings of our cell-based assay.

Collectively, our results demonstrate that the SARS-CoV-2 spike binds mink ACE2 with limited affinity. However, the Y453F mutation dramatically increased the binding affinity with mink ACE2 without compromising binding to human ACE2, which suggests that Y453F is an adaptive mutation to improve its fitness in a new host—mink.

Structural basis for the enhanced binding of mink ACE2 with Y453F RBD

To elucidate at the atomic level the molecular basis for the enhanced binding, we determined the crystal structure of SARS-CoV-2 Y453F RBD bound to mink ACE2 at 3.01 Å resolution (**Table 1**). The overall binding mode of Y453F RBD to mink ACE2 was very similar to that of WT RBD to human ACE2²¹ (**Fig. 3A and Table S1**) as evidenced by the low root mean square deviation (RMSD) value of 0.9 Å for the aligned 597 Cα atoms. A surface of 1668 Å² is buried at the binding interface of Y453F RBD/mink ACE2 and is comprised of 18 residues from Y453 RBD and 18 residues from mink ACE2. The WT RBD/human ACE2 binding interface has a similar buried surface of 1687 Å², made of 17 WT RBD residues and 20 human ACE2 residues.

Between mink ACE2 and human ACE2, there are differences in five of the amino acids involved in RBD binding: L24 (mink ACE2)/Q24 (human ACE2), E30/D30, Y34/H34, E38/D38 and H354/G354 (**Table S1**). We especially focused on the residue at ACE2 position 34 as it directly interacts with RBD residues including that at position 453. Structural analysis indicated that the Y453F substitution in the spike RBD is a species-specific adaptive mutation increasing the binding to mink ACE2 (**Fig. 3B and Table S1**). At the WT RBD/human ACE2 interface, RBD Y453 interacts with H34 of human ACE2 and the change to Tyr, as seen in mink ACE2, results in a bulkier side chain that may increase steric clashes and disfavor the binding of WT RBD to mink ACE2 (**Fig. 3B**). However, with the mutation to Phe at position 453 in the RBD, the Tyr at position 34 in mink ACE2 does not face the same steric clashes (**Fig. 3B**). In addition, while the human ACE2 H34 also has interactions with WT RBD L455 and Q493, mink ACE2 Y34 interacts with residue R403

in addition to L455 and Q493 (**Fig. 3B and Table S1**). These differing interactions may account for the enhanced binding of Y453F RBD to mink ACE2. Finally, it is also predicted that the Y453F mutation would not bring steric clashes with human ACE2 H34 and thus would not significantly change the surrounding interactions, which may explain the retained binding of Y453F RBD to human ACE2.

The Y453F mutation in miSARS-CoV-2 spike increases its interaction with other *Mustela* ACE2 orthologs

Mink is a member of the *Mustela* genus which also includes stoats and ferrets, the latter of which have been used as animal models owing to their susceptibility to SARS-CoV-2²⁵. Due to the high similarity of ACE2 proteins in the *Mustela* genus (**Fig. S4A**), we performed the binding experiments of the S1 variants (WT or Y453F) with ferret and stoat ACE2. Consistent with the results of mink ACE2, ferret and stoat ACE2 exhibited limited binding capability with WT S1-Fc but increased binding ability with S1 (Y453F)-Fc (**Fig. 4A**). As before, we confirmed that the ACE2 orthologs expressed and localized at the cell surface at comparable levels to exclude the possibility that differences in binding capability were due to variation in ACE2 expression and/or mislocalization (**Fig. 4B and Fig. S4B**). In line with our cell-based binding assay, SPR analysis did not detect the binding of WT RBD with ferret or stoat ACE2, but Y453F RBD could bind ferret or stoat ACE2 with a K_D of 31.17nM and 48.06 nM, respectively (**Fig. 4C**). Taken together, all of these results suggest that the Y453F mutation increases SARS-CoV-2 RBD binding affinity with *Mustela* ACE2 orthologs.

Y453F spike utilized mink ACE2 with enhanced efficiency for cell entry

To further demonstrate the biological consequences of the enhanced binding affinity of S1 (Y453F) with *Mustela* ACE2, we generated MLV retroviral particles (Fluc as the reporter) pseudotyped with SARS-CoV-2 WT spike (SARS-CoV-2pp) or variant Y453F

(SARS-CoV-2pp Y453F) (**Fig. 5A**). A549 cells transduced with ACE2 orthologs were inoculated with the pseudotyped virus, and luciferase (Luc) activity assayed 48h later to determine entry efficiency. Mouse ACE2 was included as a negative control. As expected, Luc activities were limited in A549-mouse ACE2 cells infected with WT or Y453F SARS-CoV-2pp. However, Luc activity increased by 350 and 400 fold in A549-human ACE2 cells infected with WT or Y453F SARS-CoV-2pp, respectively, compared to that of A549-mouse ACE2. In mink or ferret ACE2-transduced cells infected with SARS-CoV-2pp, the Luc activity increased by 9 or 12 fold relative to that of mouse ACE2, respectively. The signal was further enhanced in A549-mink ACE2 or A549-ferret ACE2 cells inoculated with SARS-CoV-2pp Y453F (110- or 120-fold, respectively, compared to A549-mouse ACE2). These results suggest that the adaptive Y453F mutation can enhance interaction with *Mustela* ACE2 and consequently promote virus entry.

In addition, utilizing the recently developed SARS-CoV-2 transcription and replication-competent virus-like particles (trVLP) cell culture system, in which the SARS-CoV-2 complete life cycle is recapitulated in cells expressing SARS-CoV-2 N gene *in trans*²⁶, we produced SARS-CoV-2 GFP/ Δ N trVLPs (WT or Y453F). We knocked out endogenous ACE2 in Caco-2 cells expressing the viral N gene (Caco-2-N) using the CRISPR-Cas9 system²⁷, and then overexpressed human (Caco-2^{ACE2KO}-N-hACE2) or mink ACE2 (Caco-2^{ACE2KO}-N-miACE2) (**Fig. S6**). Next, we inoculated the Caco-2^{ACE2KO}-N-hACE2 and Caco-2^{ACE2KO}-N-miACE2 cells with the same amount of SARS-CoV-2 GFP/ Δ N trVLP or SARS-CoV-2 GFP/ Δ N (Y453F) trVLP to achieve similar levels of initial infection. After 36 hours, the cells were collected and virus infection, as evidenced by GFP expression, was quantified by flow cytometry (**Fig. 5B**). As expected, SARS-CoV-2 trVLP replicated and spread well over time in Caco-2^{ACE2KO}-N-hACE2 cells but not in Caco-2^{ACE2KO}-N-miACE2 cells. By contrast, SARS-CoV-2 (Y453F) trVLP replicated and spread well in both cell lines (**Fig. 5B**), consistent with our binding experiments and pseudotyped virions assays (**Fig. 2B, 2E, 4A and Fig. 5A**). In sum, these results confirm that Y453F is an adaptive mutation in the SARS-CoV-2 spike protein that dramatically enhances utilization of mink ACE2 for entry, conferring a fitness advantage in the mink host.

Sensitivity of miSARS-CoV-2 variant to neutralization by convalescent sera and ACE2-Ig

SARS-CoV-2 infection elicits neutralizing antibodies that target the spike protein and are critical for protection from re-infection²⁸. Given that the mink variant contains several mutations in the spike protein, these mutations might contribute to the evasion of neutralizing antibodies. Therefore, we sought to evaluate the sensitivity of SARS-CoV-2 mink variant to neutralization by convalescent serum. We collected convalescent sera from 10 patients who contracted SARS-CoV-2 (**Fig. 5A**). We produced MLV virions pseudotyped with WT or Y453F spike and then measured the neutralization activity of convalescent sera against these viruses (**Fig. 5B**). The results showed that neutralization of particles bearing the Y453F S protein was almost 3.5-fold less efficient than those bearing the WT protein. This result suggests that the mink variant might evade neutralization by antibodies that mediate protection against COVID-19 in convalescent patients.

Soluble human ACE2 protein can bind to the S protein of SARS-CoV-2 and thus block the interaction between viral spike protein and cell-surface ACE2, thereby decreasing entry of the virus into tissue²⁹. As the miSARS-CoV-2 spike exhibited increased binding affinity with human ACE2, it is conceivable that it could be effectively blocked by soluble human ACE2 protein. To this end, we determined the antiviral potency of a recombinant ACE2-Ig variant (human ACE2 aa18-740 fused to an IgG Fc fragment) against WT or mink variant SARS-CoV-2 (Cluster Five) spike (**Fig.1A**). As shown in **Fig. 6B**, ACE2-Ig effectively inhibited virions pseudotyped with either WT or mink variant spike at an IC₅₀ of 62.7ng/ml and 65.7ng/ml, respectively.

Taken together, our data demonstrate that the miSARS-CoV-2 spike potentially evolved to escape neutralization by convalescent serum but still remains sensitive to an ACE2-based therapeutic strategy.

Discussion

Minks can act as a reservoir of SARS-CoV-2, circulating the virus among them and thus becoming a source for virus spill-over into humans as observed in the Netherlands^{14,18}. The miSARS-CoV-2 variants harbor mutations in the spike protein, which potentially could alter its transmission, pathogenicity, and/or sensitivity to vaccine-elicited immunity. In this study, we demonstrated that the Y453F substitution in the miSARS-CoV-2 spike protein is an adaptive mutation that significantly enhances interaction with mink ACE2 and promotes infection of minks. Moreover, the Y453F substitution does not compromise the ability of the spike protein to utilize human ACE2, explaining at least in part the circulation of the mink-associated virus observed in humans. The miSARS-CoV-2 variant exhibited partial resistance to neutralization by convalescent sera, suggesting that the variant has the potential to also escape protection induced by infection or vaccines.

The interaction of spike with ACE2 is a major genetic determinant of SARS-CoV-2 host range^{4,7,30,31}, and thus changes in the spike protein can adapt the virus to new hosts. Our findings revealed that SARS-CoV-2 was genetically flexible in its ability to adapt to new hosts. As we have shown, SARS-CoV-2 spike has limited binding capability to mink ACE2 (**Fig. 2B and E**), and our previous work demonstrated that mink ACE2 supported SARS-CoV-2 entry at 20% the efficiency of human ACE2⁷. It is conceivable that after transmission from humans to minks, the virus evolved further in mink to adapt to the new host, with efficient binding of SARS-CoV-2 S protein to mink ACE2 a prerequisite for ready transmission among minks. Of interest, a recent study reported the absence of natural SARS-CoV-2 human-to ferret transmission in a high-exposure setting, and genetic analysis suggested that infection of ferrets may require viral adaptation³². Here we demonstrate that the emergence of Y453F in SARS-CoV-2 spike significantly enhanced its interaction with other *Mustela* ACE2 orthologs—namely ferret and stoat—conferring a potential fitness advantage in *Mustela* species that could subsequently promote virus transmission and possible risk of animal-adapted virus with genetic alterations to spilling over into humans.

Since the spike protein is a major target for prophylactic vaccines and antibody-based

therapeutics, such mutations could have implications for treatment, diagnostic tests and viral antigenicity. It has been shown that the D614G substitution in the SARS-CoV-2 spike can promote virus entry into host cells and enhance infectivity as well as make the mutant virus resistant to neutralizing antibody^{33,34}. The Y453F mutation was shown to be an escape mutation for the monoclonal antibody RGN10933³⁵. Our results showed that miSARS-CoV-2 Y453F spike pseudotyped virions exhibited 3.5-fold resistance to neutralization by convalescent serum (**Fig. 6A**), suggesting the antibody response induced by infection or vaccine might not offer sufficient protection against mink-associated SARS-CoV-2 variant infection. However, the miSARS-CoV-2 was still sensitive to ACE2-Ig, which suggests that ACE2-based therapeutics may represent an effective antiviral strategy against the continued emergence of new variants.

In summary, our study suggests that Y453F is an adaptive mutation in SARS-CoV-2 that results in a virus more competent for infection and transmission among mink. In addition, the miSARS-CoV-2 Y453F spike mutant maintained its ability to interact with human ACE2 and exhibited partial resistance to neutralizing antibodies, potentially explaining the ability of miSARS-CoV-2 to transmit back to humans and subsequent human-human transmission. Thus, it remains an urgent need to identify potential zoonotic reservoirs of SARS-CoV-2 and to monitor the evolution of the virus in zoonotic hosts to prevent future outbreaks and develop appropriate countermeasures.

ACKNOWLEDGEMENTS

We wish to acknowledge Di Qu, Zhiping Sun, Wendong Han and other colleagues at the Biosafety Level 3 Laboratory of Fudan University for help with experiment design and technical assistance. We thank the staffs from BL17B/BL18U1/BL19U1/BL19U2/BL01B beamline of National Facility for Protein Science in Shanghai (NFPS) at Shanghai Synchrotron Radiation Facility, for assistance during data collection. We thank Dr. Jenna M. Gaska for suggestions and revision of the manuscript.

This work was supported by National Natural Science Foundation of China (32041005), Tsinghua-Peking University Center of Life Sciences (045-61020100120), Start-up Foundation of Tsinghua University (53332101319).

MATERIALS AND METHODS

Cell culture. HEK293T (American Tissue Culture Collection, ATCC, Manassas, VA, CRL-3216), A549 (ATCC #CCL-185), Vero E6 (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) and HeLa (ATCC #CCL-2) cells were maintained in Dulbecco's modified Eagle medium (DMEM) (Gibco, NY, USA) supplemented with 10% (vol/vol) fetal bovine serum (FBS), 10mM HEPES, 1mM sodium pyruvate, 1×non-essential amino acids, and 50 IU/ml penicillin/streptomycin in a humidified 5% (vol/vol) CO₂ incubator at 37°C. Cells were tested routinely and found to be free of mycoplasma contamination.

Plasmids. The cDNAs encoding human or mink ACE2 were synthesized by GenScript and cloned into pLVX-IRES-zsGreen1 vectors (Catalog No. 632187, Clontech Laboratories, Inc) with a C-terminal FLAG tag. ACE2 mutants were generated by Quikchange (Stratagene) site-directed mutagenesis. All of the constructs were verified by Sanger sequencing.

Lentivirus production. Vesicular stomatitis virus G protein (VSV-G) pseudotyped lentiviruses expressing ACE2 orthologs tagged with FLAG at the C-terminus were produced by transient co-transfection of the third-generation packaging plasmids pMD2G (Addgene #12259) and psPAX2 (Addgene #12260) and the transfer vector with VigoFect DNA transfection reagent (Vigorous) into HEK293T cells. The medium was changed 12 h post transfection. Supernatants were collected at 24 and 48h after transfection, pooled, passed through a 0.45-μm filter, and frozen at -80°C.

Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) immunoblotting was performed as follows: After trypsinization and cell pelleting at 2,000 × g for 10 min, whole-cell lysates were harvested in RIPA lysis buffer (50 mM Tris-HCl [pH 8.0], 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease inhibitor cocktail (Sigma). Lysates were electrophoresed in 12% polyacrylamide gels and transferred onto nitrocellulose membrane. The blots were blocked at room temperature for 0.5 h using 5% nonfat milk in 1× phosphate-buffered saline (PBS) containing 0.1% (v/v) Tween 20. The blots were exposed to primary antibodies anti-β-Tubulin (CW0098, CWBIO), or anti-FLAG (F7425, Sigma) in 5% nonfat

milk in 1× PBS containing 0.1% Tween 20 for 2 h. The blots were then washed in 1× PBS containing 0.1% Tween 20. After 1h exposure to HRP-conjugated secondary antibodies, subsequent washes were performed and membranes were visualized using the Luminescent image analyzer (GE).

Surface ACE2 binding assay. HeLa cells were transduced with lentiviruses expressing the ACE2 from different species for 48 h. The cells were collected with TrypLE (Thermo #12605010) and washed twice with cold PBS. Live cells were incubated with the recombinant protein, S1 domain of SARS-CoV-2 spike C-terminally fused with Fc (Sino Biological #40591-V02H, 1µg/ml) at 4°C for 30 min. After washing, cells were stained with goat anti-human IgG (H + L) conjugated with Alexa Fluor 647 (Thermo #A21445, 2 µg/ml) for 30 min at 4°C. Cells were then washed twice and subjected to flow cytometry analysis (Thermo, Attune™ NxT).

Production of SARS-CoV-2 pseudotyped virus. Pseudoviruses were produced in HEK293T cells by co-transfecting the retroviral vector pTG-MLV-Fluc, pTG-MLV-Gag-pol, and pcDNA3.1 expressing SARS-CoV-2 spike gene or VSV-G (pMD2.G, Addgene #12259) using VigoFect (Vigorous Biotechnology). At 48 h post transfection, the cell culture medium was collected for centrifugation at 3500 rpm for 10 min, and then the supernatant was subsequently aliquoted and stored at -80°C for further use. Virus entry was assessed by transduction of pseudoviruses in A549 cells expressing ACE2 orthologs or mutants in 48-well plates. After 48 h, intracellular luciferase activity was determined using the Luciferase Assay System (Promega, Cat. #E1500) according to the manufacturer's instructions. Luminescence was recorded on a GloMax® Discover System (Promega).

Protein expression and purification. The SARS-CoV-2 RBD (residues Arg319–Phe541) and the N-terminal peptidase domain of human ACE2 (residues Ser19–Asp615) were expressed using the Bac-to-Bac baculovirus system (Invitrogen) as described previously²¹. ACE2-Ig, a recombinant Fc fusion protein of soluble human ACE2 (residues Gln18-Ser740), was expressed in 293F cells and purified using protein A affinity chromatography as described in our previous study³⁶.

Surface plasmon resonance analysis. ACE2 was immobilized on a CM5 chip (GE Healthcare) to a level of around 500 response units using a Biacore T200 (GE Healthcare) and a running buffer (10 mM HEPES pH 7.2, 150 mM NaCl and 0.05% Tween-20). Serial dilutions of the SARS-CoV-2 RBD were flowed through with a concentration ranging from 400 to 12.5 nM. The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software (GE Healthcare).

Protein crystallization. The gene encoding 333-527aa of SARS-CoV-2 RBD (WT or Y453F mutant) was cloned into the pFastbac-dual vector using the BamH1 and Hind3 restriction enzyme. A GP67 signal peptide was added to the N-terminus for protein secretion and a 6×His tag was added to the C-terminus for protein purification as described previously²¹. The gene encoding 1-615aa of ACE2 from human or mink was constructed in the same way as SARS-CoV-2 RBD except using its own peptide for protein secretion. All the proteins were expressed using Hi5 cells. Briefly, baculovirus containing the gene of SARS-CoV-2 RBD or ACE2 were produced according to the Invitrogen bac-to-bac Baculovirus Expression System Manual. To purify the protein, supernatant was collected 60h after cell transfection, then buffer-exchanged to 1×HBS (10mM HEPES, 150mM NaCl, pH7.2), and was loaded on a Ni column equilibrated with the same buffer. After washing the column with 1×HBS containing 20mM Imidazole, the protein was eluted by 1×HBS containing 500mM Imidazole. The protein was further concentrated and purified by gel filtration chromatography on a Superdex 200 10/300 column in the 1×HBS buffer. To prepare the RBD and ACE2 complex, ACE2 and RBD were mixed as a molar ratio of 1:1.5 and incubated at 4°C for 60 minutes, then purified by gel filtration chromatography in TBS buffer (25mM Tris, 150mM NaCl, pH 7.5). Fractions were collected and concentrated to 13mg/ml for crystal screening. Kits used in crystal screening were all purchased from Hampton Research. The crystal of SARS-CoV-2 RBD Y453F and mink ACE2 complex was obtained in a well solution of 1.6 M sodium/potassium phosphate using the sitting drop method.

Data collection and refinement. Diffraction data were collected at 100 K and at a

wavelength of 0.9796 Å on the BL18U1 beam line of the Shanghai Synchrotron Research Facility. The diffraction data were then processed using the HKL2000. The two structures were determined using the molecular replacement method with Molrep in the CCP4 suite³⁷, using the model of the human ACE2 and SARS-CoV-2 complex²¹. There were three complex molecules in one asymmetric unit. Subsequent model building and refinement were performed using COOT and PHENIX, respectively^{38,39}. The data-processing statistics and structure refinement statistics are listed in **Table 1**. All structure figures were generated with PyMol⁴⁰. The coordinates and structure factor files for the SARS-CoV-2 Y453F RBD/mink ACE2 complex have been deposited in the Protein Data Bank (PDB) under accession number 7F5R.

Convalescent serum. We obtained convalescent serum from 10 patients (**Table S2**, one patient's information is not complete) more than one month after documented SARS-CoV-2 infection in the spring of 2020. Among these 10 patients, 9 patients information was recorded. Three had severe disease and 6 had non-severe disease. Their ages ranged from 24 to 69, with a mean of 54. Eight were male, and 1 was female. Each plasma sample was heat-inactivated (56°C, 30 min) and then assayed for neutralization against WT or mink-variant pseudoviruses. This study was approved by the Institution Review Board of Tsinghua University (20210040).

SARS-CoV-2 pseudovirus neutralization assay. SARS-CoV-2 spike variant-pseudotyped luciferase reporter viruses were pre-diluted in DMEM (2% FBS, heat-inactivated) containing serially diluted convalescent serum. Virus-serum mixtures were incubated at 37°C for 30min, then added to A549-hACE2 cells in 96-well plates and incubated at 37°C. After 48 h, intracellular luciferase activity was determined using the Luciferase Assay System (Promega, Cat. #E1500) according to the manufacturer's instructions. Luminescence was recorded on a GloMax Discover System (Promega). The NT50 (Neutralizing titer 50) was defined as the serum dilution factor that leads to 50% reduction in spike protein-driven cell entry.

Statistics analysis. One-way analysis of variance (ANOVA) with Tukey's honestly

429 significant difference (HSD) test was used to test for statistical significance of the
430 differences between the different group parameters. *P* values of less than 0.05 were
431 considered statistically significant.

432

TABLES

Table 1. Data collection and refinement statistics

Y453F RBD/mink ACE2	
Data collection	
Space group	P2 ₁ 2 ₁ 2
Cell dimensions	
a,b,c (Å)	290.19, 130.19, 136.89
α,β,γ (°)	90, 90, 90
Resolution (Å)	43.53-3.01(3.12-3.01)
Rsym of Rmerge	0.252(1.5)
I/si	11.3(1.5)
Completeness (%)	98.12(93.39)
Redundancy	9.8(9.1)
Refinement	
Resolution (Å)	43.53-3.01
Reflections	101417
Rwork/Rfree	0.18/0.22
Atoms	
Protein	19222
Ligand	170
B-factors	
Protein	65.29
Ligand	95.00
Rms deviations	
Bond lengths (Å)	0.010
Bond angles (°)	1.07

Values for high resolution shell are given in parentheses

Figures and Figure legends

Figure 1. The mutation Y453F in SARS-CoV-2 spike protein is a potential genetic adaptation in minks. (A) Schematic of amino acid changes in the spike protein of miSARS-CoV-2 variant "Cluster 5". The four genetic changes in the S protein are marked in red. NTD, N-terminal domain; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane region; IC, intracellular domain. (B) Alignment of the residues of human (*Homo sapiens*; NCBI Reference Sequence: NM_001371415.1), mink (*Neovison vison*; NCBI Reference Sequence: MW269526.1), ferret (*Mustela putorius furo*; NCBI Reference Sequence: NM_001310190.1) and stoat (*Mustela erminea*; NCBI Reference Sequence: XM_032331786.1) ACE2 at the interface of ACE2 with the SARS-CoV-2 spike protein. The position of Y453 in the SARS-CoV-2 RBD is colored in red. The Y34 of mink, ferret and stoat ACE2 are highlighted in red. (C) Structural features of the SARS-CoV-2 RBD and ACE2. Contacting residues are shown as sticks at the hACE2-SARS-CoV-2 RBD interfaces (PDB ID: 6M0J). The key residues Y453 of the RBD and H34 of human ACE2 (left) are labeled. The position of the Y34 substitution in human ACE2 (right) is labeled. SARS-CoV-2 RBD is shown in cyan, ACE2 in green. The dashed lines indicate hydrogen bonds.

Figure 2. Increased binding of Y453F spike protein to mink ACE2. (A) Schematic of testing the efficiency of ACE2 variants binding WT or Y453F viral spikes. (B) HeLa cells were transduced with human and mink ACE2 or their mutants as indicated. The transduced cells were incubated with the WT or Y453F S1 domain of SARS-CoV-2 C-terminally fused with a His tag and then stained anti-His-PE for flow cytometry analysis. Values are expressed as the percent of cells positive for S1-Fc among the ACE2-expressing cells (zsGreen1+ cells) and shown as the means $\pm$ SD from 3 biological replicates. These experiments were independently performed three times with similar results. (C) Representative immunoblots of HeLa cells transduced with lentiviruses expressing FLAG-tagged ACE2. Actin used as the loading control.

These experiments were independently performed twice with similar results. (D) Cell surface localization of human and mink ACE2 and their mutants. HeLa cells were transduced with lentivirus expressing human or mink ACE2 and their mutants. Cells were incubated with rabbit polyclonal antibody against ACE2 and then stained with goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 568 and DAPI (1µg/ml). The cell images were captured with a Zeiss LSM 880 Confocal Microscope. This experiment was independently repeated twice with similar results and the representative images are shown. (E) Table summarizing biochemical results for ACE2 variants bound to WT or Y453F RBD. These experiments were independently performed three times with similar results.

473

474 **Figure 3. Structural comparison of Y453F RBD/mink ACE2 and WT RBD/human**
475 **ACE2 complexes.** (A) The overall structure is shown as ribbons. The Y453F-RBD is shown
476 in cyan and mink ACE2 in green. The WT-RBD and human ACE2 are shown in magenta
477 and orange, respectively. (B) Interaction residues around position 34 of human and mink
478 ACE2. Left: complex of Y453F RBD/mink ACE2. Right: complex of WT RBD/human ACE2.
479 RBD is shown in cyan, ACE2 in green. Contact residues are shown as sticks which were
480 defined using a distance cutoff of 4Å. Q493 of WT-RBD has a double conformation. The
481 PDB code for WT-RBD/human ACE2 complex is 6M0J²¹.

482

483

484 **Figure 4. Increased binding of Y453F spike protein to *Mustelidae* ACE2 orthologs.** (A)
485 HeLa cells were transduced with human or *Mustelidae* ACE2 orthologs as indicated.
486 Transduced cells were incubated with WT or Y453F S1 domain of SARS-CoV-2 C-terminally
487 fused with His tag and then stained with anti-His-PE for flow cytometry analysis. Values are
488 expressed as the percent of cells positive for S1-Fc among the ACE2-expressing cells
489 (zsGreen1+ cells) and shown as the means ± SD from 3 biological replicates. These

experiments were independently performed three times with similar results. (B) Cell surface localization of human, ferret and stoat ACE2. HeLa cells were transduced with lentivirus expressing ACE2 orthologs as indicated. Cells were incubated with rabbit polyclonal antibody against ACE2 and then stained with goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 568 and DAPI (1µg/ml). The cell images were captured with a Zeiss LSM 880 Confocal Microscope. This experiment was independently repeated twice with similar results and the representative images are shown. (C) The binding kinetics of ACE2 proteins (ferret or stoat) with recombinant WT or Y453F SARS-CoV-2 RBD were obtained using the BIAcore. ACE2 proteins were captured on the chip, and serial dilutions of RBD were then injected over the chip surface. Experiments were performed three times with similar result, and one set of representative data is displayed.

503

504 **Figure 5. Enhanced infection of Y453F spike pseudotyped virion or trVLP in Caco-2 cells**
505 **expressing exogenous mink ACE2.** (A) HeLa cells transduced with mouse ACE2, human
506 ACE2, mink ACE2 or ferret ACE2 were infected with WT or Y453F SARS-CoV-2
507 pseudoparticles. Two days after infection, cells were lysed and luciferase activity determined.
508 All infections were performed in triplicate, and the data are representative of two independent
509 experiments (mean ± SD). *, P < 0.05, **, P < 0.01. Significance assessed by one-way ANOVA.
510 (B-C) Endogenous ACE2 knockout Caco-2 cells expressing SARS-CoV-2 N protein were
511 infected with SARS-CoV-2 GFP/ΔN (MOI=0.1). After 36 hours, GFP expression was observed

using immunofluorescence microscopy and GFP-positive cells were quantified by flow cytometry. All infections were performed in triplicate, and the data are pooled from two independent experiments (mean $\pm$ SD). *, $P < 0.05$, **, $P < 0.01$. Significance assessed by one-way ANOVA.

Figure 6. Sensitivity of miSARS-CoV-2 “Cluster Five” spike pseudotyped virus to neutralization by convalescent sera of patients or soluble ACE2. (A) Convalescent serum samples from donors were serially diluted and incubated with WT or “Cluster Five” spike-pseudotyped viruses. The serum dilution factor leading to 50% reduction of pseudotyped virion entry was calculated as the NT₅₀ (neutralizing titer 50). Identical plasma samples are connected with lines. These analyses were repeated twice with similar results. Statistical analysis of the difference between neutralization of the WT and “Cluster Five” was performed using two-tailed Wilcoxon matched-pairs signed-rank test. (B) Recombinant ACE2-Ig was diluted at the indicated concentrations. Viral entry was determined by assessing Luc activity 48 hours post infection. The dilution factors leading to 50% reduction of pseudotyped virion entry was calculated as the IC₅₀. Data shown are representative of three independent experiments with similar results, and data points represent mean ± SD in triplicate.

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS

Supplemental Figure 1. Cell surface expression of human and mink ACE2. (A) HeLa cells transduced with lentiviruses (pLVX-IRES-zsGreen) expressing mouse, human (WT or H34Y) or mink ACE2 (WT or Y34H) were incubated with rabbit polyclonal antibody (Sino Biological Inc. China, Cat: 10108-T24) against ACE2. The cells were washed and then stained with 2µg/mL goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 568 for flow cytometry analysis. The cell surface ACE2 was calculated as the percent of Alex Fluor 568-positive cells among the zsGreen-positive cells. This experiment was repeated twice with similar results. (B) HeLa cells transduced with lentiviruses (pLVX-IRES-zsGreen) expressing mouse, human, mink, ferret or stoat ACE2 were analyzed as described in (A) panel. This experiment was repeated twice with similar results.

545

546 **Supplemental Figure 2. Gating strategy for determining the binding efficiency of different**
 547 **ACE2 orthologs with SARS-CoV-2 S1 protein.** The main cell population was identified and
 548 gated on Forward and Side Scatter. Single cells were further gated on FSC-A and FSC-H. The
 549 gated cells were plotted by FITC-H (zsGreen, the ACE2 -expressing population) and APC-H or
 550 PE-Texas Red-H (S1-Fc bound population). The APC-H or PE-Texas Red-H positive cell
 551 population was plotted as a histogram to show the S1-Fc positive population as in Fig 2A. The
 552 binding efficiency was defined as the percent of S1-Fc binding cells among the zsGreen-
 553 positive cells. Shown are FACS plots representative of those used for the calculations of binding

554 efficiencies of ACE2 orthologs with S1-Fc. All binding assays were performed in duplicate.

555

556

557

558 **Supplemental Figure 3. SPR analysis of the binding affinity of ACE2 variants with WT or**
559 **Y453F RBD.** (A) The N-terminal peptidase domain of each ACE2 variant (residues Met1-
560 Asp615), WT or Y453F SARS-CoV-2 RBD (residues Thr333-Pro527) were expressed and
561 purified as described in the *Materials and Methods*. The purified proteins were analyzed by
562 SDS-PAGE with Coomassie blue staining. (B) The binding kinetics of ACE2 variant proteins
563 (human or mink) with recombinant WT or Y453F SARS-CoV-2 RBD were obtained using the
564 BIAcore. ACE2 proteins were captured on the chip, and serial dilutions of RBD were then
565 injected over the chip surface. Experiments were performed three times with similar results,
566 and one set of representative data is displayed.

567

568

569 **Supplemental Figure 4. Expression of *Mustelidae* species ACE2 orthologs in HeLa cells.**

570 (A) Alignment of ACE2 orthologs of the *Mustelidae* species mink, ferret and stoat. (B)

571 Representative immunoblots of HeLa cells transduced with lentiviruses expressing FLAG-

572 tagged ACE2 orthologs as indicated. Actin used as the loading control. These experiments

573 were independently performed twice with similar results.

574

575

576

Supplemental Figure 5. Gating strategy for determination of the binding efficiency of *Mustelidae* species ACE2 with SARS-CoV-2 S1 protein. The main cell population was identified and gated on Forward and Side Scatter. Single cells were further gated on FSC-A and FSC-H. The gated cells were plotted by FITC-H (zsGreen, as the ACE2-expressing population) and APC-H or PE-Texas Red-H (S1-Fc bound population). The APC-H or PE-Texas

Red-H positive cell population was plotted as a histogram to show the S1-Fc positive population as in Fig 2D. The binding efficiency was defined as the percent of S1-Fc binding cells among the zsGreen-positive cells. Shown are FACS plots representative of those used for the calculations of binding efficiencies of ACE2 orthologs with S1-Fc.

Supplemental Figure 6. Ectopic expression of human ACE2 and mink ACE2 in Caco-2^{ACE2KO}-N cells. Caco-2^{ACE2KO}-N cells were transduced with lentivirus expressing human ACE2 or mink ACE2. Immunoblotting assay was performed to detect the expression of human ACE2 and mink ACE2. Actin was used as the loading control. These experiments were independently performed twice with similar results.

SUPPLEMENTAL TABLES

Table S1. Comparison of contact residues on the interfaces of SARS-CoV-2 WT RBD/human ACE2 and Y453F RBD/mink ACE2.

Y453F RBD	Mink ACE2	WT RBD	Human ACE2
R403	Y34	R403	
K417	E30	K417	D30
G446		G446	Q42
Y449	E38, Q42	Y449	D38, Q42
F453	Y34	Y453	H34
L455	Y34	L455	H34
F456	T27, E30	F456	T27, D30
A475	S19, L24	A475	Q24, T27
G476	L24	G476	
F486		F486	L79, M82, Y83
N487	L24, Y83	N487	Q24, Y83
Y489	T27, F28, Y83	Y489	T27, F28, K31, Y83
Q493	K31, Y34	Q493	K31, H34, E35
Y495	E38	Y495	
G496	E38, K353	G496	K353
Q498	E38, Y41, Q42, K353	Q498	Y41, Q42
T500	Y41, N330, D355, R357	T500	Y41, N330, D355, R357
N501	Y41, K353	N501	Y41, K353
G502	K353, H354, D355	G502	K353, G354
Y505	E37, K353, H354, R393	Y505	E37, K353, G354, R393

A distance of 4 Å was defined as interaction residues.

605

606 **Table S2. Summary of COVID-19 patients' information.**

Characteristics	Patients (n=9)
Age (median, range)	54 (24-69)
Sex	
Male (%)	8 (88.9)
Female (%)	1 (11.1)
Disease severity	
Severe	3 (33.3)
Non-severe	6 (66.7)
Comorbidities, n (%)	
Fever	6 (66.7)
Fatigue	4 (44.4)
Dry cough	2 (22.2)
Dyspnea	3 (33.3)
Expectoration	4 (44.4)
Diarrhea	1 (11.1)
Chills	2 (22.2)
Chest stuffiness	3 (33.3)

608

609

610

611

References

- 1 Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol* **7**, 439–450, doi:10.1038/nrmicro2147 (2009).
- 2 Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. *Nat Rev Microbiol* **11**, 836–848, doi:10.1038/nrmicro3143 (2013).
- 3 Xiong, Y. *et al.* Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerging Microbes & Infections* **9**, 761–770, doi:10.1080/22221751.2020.1747363 (2020).
- 4 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271–280 e278, doi:10.1016/j.cell.2020.02.052 (2020).
- 5 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273, doi:10.1038/s41586-020-2012-7 (2020).
- 6 Douam, F. *et al.* Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. *Annu Rev Genet* **49**, 21–45, doi:10.1146/annurev-genet-112414-054823 (2015).
- 7 Liu, Y. *et al.* Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. *Proc Natl Acad Sci U S A* **118**, doi:10.1073/pnas.2025373118 (2021).
- 8 Munster, V. J. *et al.* Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. *Nature* **585**, 268–272, doi:10.1038/s41586-020-2324-7 (2020).
- 9 McAloose, D. *et al.* From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo. *mBio* **11**, doi:10.1128/mBio.02220-20 (2020).
- 10 Segalés, J. *et al.* Detection of SARS-CoV-2 in a cat owned by a COVID-19–affected patient in Spain. *Proceedings of the National Academy of Sciences*, doi:10.1073/pnas.2010817117 (2020).
- 11 Shi, J. *et al.* Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science* **368**, 1016–1020, doi:10.1126/science.abb7015 (2020).
- 12 Sia, S. F. *et al.* Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **583**, 834–838, doi:10.1038/s41586-020-2342-5 (2020).
- 13 Sit, T. H. C. *et al.* Infection of dogs with SARS-CoV-2. *Nature*, doi:10.1038/s41586-020-2334-5 (2020).
- 14 Oude Munnink, B. B. *et al.* Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science* **371**, 172–177, doi:10.1126/science.abe5901 (2021).
- 15 Hammer, A. S. *et al.* SARS-CoV-2 Transmission between Mink (*Neovison vison*) and Humans, Denmark. *Emerg Infect Dis* **27**, 547–551, doi:10.3201/eid2702.203794 (2021).
- 16 Oreshkova, N. *et al.* SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.23.2001005 (2020).
- 17 van Dorp, L. *et al.* Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation. – 2020.2011.2016.384743.
- 18 Koopmans, M. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. *Lancet Infect Dis* **21**, 18–19, doi:10.1016/S1473-3099(20)30912-9 (2021).

654 19 Hayashi, T., Yaegashi, N. & Konishi, I. Effect of RBD mutation (Y453F) in spike glycoprotein
655 of SARS-CoV-2 on neutralizing antibody affinity. *bioRxiv* (2020).

656 20 Hoffmann, M. *et al.* SARS-CoV-2 mutations acquired in mink reduce antibody-mediated
657 neutralization. *Cell Rep* **35**, 109017, doi:10.1016/j.celrep.2021.109017 (2021).

658 21 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
659 ACE2 receptor. *Nature* **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).

660 22 Shang, J. *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221-
661 224, doi:10.1038/s41586-020-2179-y (2020).

662 23 Wang, Q. *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by Using Human
663 ACE2. *Cell* **181**, 894-904.e899, doi:10.1016/j.cell.2020.03.045 (2020).

664 24 Yan, R. *et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human
665 ACE2. *Science* **367**, 1444-1448, doi:10.1126/science.abb2762 (2020).

666 25 Kim, Y. I. *et al.* Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host*
667 *Microbe* **27**, 704-709 e702, doi:10.1016/j.chom.2020.03.023 (2020).

668 26 Ju, X. *et al.* A novel cell culture system modeling the SARS-CoV-2 life cycle. *PLoS Pathog*
669 **17**, e1009439, doi:10.1371/journal.ppat.1009439 (2021).

670 27 Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**,
671 819-823, doi:10.1126/science.1231143 (2013).

672 28 Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* **584**,
673 115-119, doi:10.1038/s41586-020-2380-z (2020).

674 29 Monteil, V. *et al.* Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using
675 Clinical-Grade Soluble Human ACE2. *Cell* **181**, 905-913.e907,
676 doi:10.1016/j.cell.2020.04.004 (2020).

677 30 Gu, H. *et al.* Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.
678 *Science* **369**, 1603-1607, doi:10.1126/science.abc4730 (2020).

679 31 Leist, S. R. *et al.* A Mouse-adapted SARS-CoV-2 induces Acute Lung Injury (ALI) and
680 mortality in Standard Laboratory Mice. *Cell*, doi:10.1016/j.cell.2020.09.050 (2020).

681 32 Sawatzki, K. *et al.* Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-
682 exposure domestic setting. *Proceedings of the National Academy of Sciences* **118**,
683 doi:10.1073/pnas.2025601118 (2021).

684 33 Korber, B. *et al.* Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
685 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827 e819, doi:10.1016/j.cell.2020.06.043
686 (2020).

687 34 Plante, J. A. *et al.* Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* **592**, 116-121,
688 doi:10.1038/s41586-020-2895-3 (2021).

689 35 Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
690 escape seen with individual antibodies. *Science* **369**, 1014-1018,
691 doi:10.1126/science.abd0831 (2020).

692 36 Li, Y. *et al.* SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs
693 and Are Potently Blocked by an Improved ACE2-Ig. *J Virol* **94**, doi:10.1128/JVI.01283-20
694 (2020).

695 37 Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. *Acta Crystallogr D Biol*
696 *Crystallogr* **66**, 22-25, doi:10.1107/S0907444909042589 (2010).

697 38 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*
698 *Crystallogr D Biol Crystallogr* **60**, 2126-2132, doi:10.1107/S0907444904019158 (2004).
699 39 Adams, P. D. *et al.* PHENIX: building new software for automated crystallographic structure
700 determination. *Acta Crystallogr D Biol Crystallogr* **58**, 1948-1954,
701 doi:10.1107/s0907444902016657 (2002).
702 40 Janson, G., Zhang, C., Prado, M. G. & Paiardini, A. PyMod 2.0: improvements in protein
703 sequence-structure analysis and homology modeling within PyMOL. *Bioinformatics* **33**,
704 444-446, doi:10.1093/bioinformatics/btw638 (2017).
705